Navigation Links
LCS Constructors, Inc. Completes First Major Phase of Abraxis BioScience Project

IRVINE, Calif., April 29 /PRNewswire/ -- Abraxis BioScience initially engaged LCS Constructors, Inc. to perform an evaluation of the former ICN/Valient Pharmaceutical building in Costa Mesa, California prior to their purchasing this 165,000 square foot building. The "due diligence report" revealed an array of issues that required repair or retro-fit prior to occupying the building, and once the building purchase was complete, Abraxis called upon LCS to serve as Design-Builder for a multi-phase renovation.

With Senior Project Manager David P. Carlos leading the way and Superintendent Jim Koons heading up daily production, LCS recently completed significant seismic upgrades as well as restoring and renovating existing laboratory space to Abraxis' specifications. LCS was charged with ensuring that the end result would be a new "state-of-the-art" laboratory which includes labs for chemistry, biology, formulation, and a Biological Safety Lab 3 (BSL3).

The biggest challenges throughout the project were, literally, the seismic upgrades. Working on the second floor, the size and weight alone of the dampeners was too much to just place them anywhere. With each dampener between 15' and 19' long and weighing between 700 lbs and 1000 lbs each, they were just too large to install without significant planning.

The team strategized to figure out the best location for the dampeners which was both close to the work but out of the way, keeping both production and safety in mind. Because the seismic dampeners were not standard equipment, the installation presented other unique challenges in terms of tolerances. Additionally, in order to accurately plan for the installation of the dampeners, seismic models were created. These seismic models were a key element for understanding the purpose and the workings for this project.

"This has been a fantastic client and job to work on," stated Koons. And, although the team faced several unique challenges that accompanied these seismic upgrades, they were resourceful and that, combined with patience, planning and strategy, led to the successful completion of the first major phase of this project.

The relocation of Abraxis' research and development group from Marina Del Rey to Costa Mesa will provide the company more space to grow their operations. LCS was proud to renovate the new facility which will provide the technology necessary to propel Abraxis closer to their goals of finding new treatments for cancer and other pathological disorders.

SOURCE LCS Constructors, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Family Rentals, a ... announced the launch of their newly designed, mobile-responsive ... --> Logo ... --> --> Now, renting essential ... and vacation, just got a whole lot easier ...
(Date:11/24/2015)... --> --> Opportunities ... and PPAR Agonists cholesterol-lowering drugs market ? ... rates? This visiongain report shows you potential ... there. ,  ,Our 199-page report provides 153 tables, charts, ... industry and the future market prospects. Our new study ...
(Date:11/24/2015)... , Nov. 24, 2015  Boston Scientific Corporation (NYSE: ... Oppenheimer 26th Annual Healthcare Conference on December 8, in ... Susie Lisa , vice president, Investor Relations, will participate ... beginning at approximately 8:35 a.m. ET. --> ... in a 30-minute question-and-answer session with the host analyst ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... ... it comes to several aspects of orthopedic care. They have received recognition for ... and general orthopedic care. , Becker's Hospital Review selected hospitals for inclusion ...
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to ... it is critical that the first impression be positive and reflects business values. If ... to buy anything or want to return. They will also share their thoughts about ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... LENR HHT Bolier Reactor System. Brillouin is the developer of renewable energy technologies ... low energy nuclear reactions (“LENR”), announced today that its WET™ and HHT™ Boiler ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... advisory organization, is pleased to welcome Winter-Dent & Company as its newest Partner ... day one to become a client's most trusted advisor regardless of whether that ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... States to support their local poison centers through donations on Tuesday, Dec. 1, ... calls it “a day that inspires people to collaborate in improving their local ...
Breaking Medicine News(10 mins):